FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129672202> ?p ?o ?g. }

• W2129672202 endingPage "R117" @default.
• W2129672202 startingPage "R117" @default.
• W2129672202 abstract "Mortality in systemic lupus erythematosus (SLE) patients is influenced by an increased occurrence of severe cardiovascular complications. Statins have been proven to protect a wide spectrum of SLE patients from these complications. This study was conducted to determine the possible efficacy of atorvastatin in SLE patients as assessed by multi-detector computed tomography (MDCT)-based coronary calcium scoring and single photon emission computed tomography (SPECT) of the myocardium. Sixty SLE patients in stable clinical conditions were randomized to receive either atorvastatin (40 mg daily; n = 28) or placebo (n = 32). Clinical and biochemical evaluation together with MDCT-based coronary calcium scoring and SPECT studies (Tc-99 m sestamibi) were performed at the time of randomization and after 1 year of treatment. At randomization, SPECT revealed perfusion defects at rest in 22 (36.7%) patients and exercise-induced defects in 8 (13.3%), whereas MDCT revealed coronary calcifications in 15 subjects (25%). Coronary calcium deposits increased after 1 year in the placebo group (plaque volume change from 35.2 ± 44.9 to 62.9 ± 72.4, P < 0.05; calcium score from 32.1 ± 39.1 to 59.5 ± 64.4; P < 0.05), but not in the atorvastatin group (plaque volume 54.5 ± 62.4 vs. 51.0 ± 47.6, P not significant; calcium score 44.8 ± 50.6 vs. 54.9 ± 62.5, P not significant). The atorvastatin group showed a decrease in total serum cholesterol (from 5.1 ± 1.2 to 4.4 ± 0.7 mmol/L, P < 0.05), LDL cholesterol (2.9 ± 1.0 to 2.3 ± 0.6 mmol/L, P < 0.05), triglycerides (1.6 ± 0.6 to 1.2 ± 0.5 mmol/L, P < 0.05), and C-reactive protein (CRP) (4.4 ± 4.1 to 2.7 ± 1.7 mg/L, P < 0.05). There was no change in the mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score in patients from both groups. Perfusion defects observed at randomization showed no change after one year treatment with atorvastatin. In SLE patients 40 mg of atorvastatin daily for 1 year led to a decrease in serum lipids and CRP levels. Additionally the progression of atherosclerosis, as assessed by MDCT-based coronary calcium scoring, is restrained by atorvastatin treatment. The value of statin treatment in patients with SLE free from cardiovascular disease clinical symptoms should be addressed in large, prospective clinical trials." @default.
• W2129672202 created "2016-06-24" @default.
• W2129672202 creator A5012061533 @default.
• W2129672202 creator A5038476377 @default.
• W2129672202 creator A5039077672 @default.
• W2129672202 creator A5060672622 @default.
• W2129672202 creator A5065094545 @default.
• W2129672202 creator A5083627470 @default.
• W2129672202 creator A5084111008 @default.
• W2129672202 date "2011-01-01" @default.
• W2129672202 modified "2023-10-14" @default.
• W2129672202 title "Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study" @default.
• W2129672202 cites W1484156179 @default.
• W2129672202 cites W1500963439 @default.
• W2129672202 cites W1525331105 @default.
• W2129672202 cites W1979012782 @default.
• W2129672202 cites W1981808022 @default.
• W2129672202 cites W1984562211 @default.
• W2129672202 cites W2005751258 @default.
• W2129672202 cites W2007050875 @default.
• W2129672202 cites W2019931017 @default.
• W2129672202 cites W2026018907 @default.
• W2129672202 cites W2054330426 @default.
• W2129672202 cites W2068939376 @default.
• W2129672202 cites W2069797332 @default.
• W2129672202 cites W2076708398 @default.
• W2129672202 cites W2091096074 @default.
• W2129672202 cites W2094352959 @default.
• W2129672202 cites W2098313122 @default.
• W2129672202 cites W2099018264 @default.
• W2129672202 cites W2102364720 @default.
• W2129672202 cites W2103445035 @default.
• W2129672202 cites W2113642869 @default.
• W2129672202 cites W2117017190 @default.
• W2129672202 cites W2118154631 @default.
• W2129672202 cites W2122146058 @default.
• W2129672202 cites W2132659447 @default.
• W2129672202 cites W2136366145 @default.
• W2129672202 cites W2145958975 @default.
• W2129672202 cites W2146228563 @default.
• W2129672202 cites W2147346175 @default.
• W2129672202 cites W2153785016 @default.
• W2129672202 cites W2155598961 @default.
• W2129672202 cites W2160152341 @default.
• W2129672202 cites W2331486639 @default.
• W2129672202 cites W4239634304 @default.
• W2129672202 doi "https://doi.org/10.1186/ar3402" @default.
• W2129672202 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3239355" @default.
• W2129672202 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21774822" @default.
• W2129672202 hasPublicationYear "2011" @default.
• W2129672202 type Work @default.
• W2129672202 sameAs 2129672202 @default.
• W2129672202 citedByCount "52" @default.
• W2129672202 countsByYear W21296722022012 @default.
• W2129672202 countsByYear W21296722022013 @default.
• W2129672202 countsByYear W21296722022014 @default.
• W2129672202 countsByYear W21296722022015 @default.
• W2129672202 countsByYear W21296722022016 @default.
• W2129672202 countsByYear W21296722022017 @default.
• W2129672202 countsByYear W21296722022018 @default.
• W2129672202 countsByYear W21296722022019 @default.
• W2129672202 countsByYear W21296722022020 @default.
• W2129672202 countsByYear W21296722022021 @default.
• W2129672202 countsByYear W21296722022023 @default.
• W2129672202 crossrefType "journal-article" @default.
• W2129672202 hasAuthorship W2129672202A5012061533 @default.
• W2129672202 hasAuthorship W2129672202A5038476377 @default.
• W2129672202 hasAuthorship W2129672202A5039077672 @default.
• W2129672202 hasAuthorship W2129672202A5060672622 @default.
• W2129672202 hasAuthorship W2129672202A5065094545 @default.
• W2129672202 hasAuthorship W2129672202A5083627470 @default.
• W2129672202 hasAuthorship W2129672202A5084111008 @default.
• W2129672202 hasBestOaLocation W21296722021 @default.
• W2129672202 hasConcept C126322002 @default.
• W2129672202 hasConcept C142724271 @default.
• W2129672202 hasConcept C146957229 @default.
• W2129672202 hasConcept C164705383 @default.
• W2129672202 hasConcept C168563851 @default.
• W2129672202 hasConcept C198451711 @default.
• W2129672202 hasConcept C204243189 @default.
• W2129672202 hasConcept C204787440 @default.
• W2129672202 hasConcept C27081682 @default.
• W2129672202 hasConcept C2777482532 @default.
• W2129672202 hasConcept C71924100 @default.
• W2129672202 hasConcept C90924648 @default.
• W2129672202 hasConceptScore W2129672202C126322002 @default.
• W2129672202 hasConceptScore W2129672202C142724271 @default.
• W2129672202 hasConceptScore W2129672202C146957229 @default.
• W2129672202 hasConceptScore W2129672202C164705383 @default.
• W2129672202 hasConceptScore W2129672202C168563851 @default.
• W2129672202 hasConceptScore W2129672202C198451711 @default.
• W2129672202 hasConceptScore W2129672202C204243189 @default.
• W2129672202 hasConceptScore W2129672202C204787440 @default.
• W2129672202 hasConceptScore W2129672202C27081682 @default.
• W2129672202 hasConceptScore W2129672202C2777482532 @default.
• W2129672202 hasConceptScore W2129672202C71924100 @default.
• W2129672202 hasConceptScore W2129672202C90924648 @default.
• W2129672202 hasIssue "4" @default.

• next